- Home
- ACP vs CSTL Comparison
ACP vs CSTL Comparison
Compare ACP & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACP | CSTL |
|---|---|---|
| Founded | 2010 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 637.4M | 722.8M |
| IPO Year | 2010 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ACP | CSTL |
|---|---|---|
| Price | $5.14 | $29.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $45.50 |
| AVG Volume (30 Days) | ★ 566.6K | 470.7K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | ★ 17.79% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $344,229,000.00 |
| Revenue This Year | N/A | $2.42 |
| Revenue Next Year | N/A | $12.69 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 3.66 |
| 52 Week Low | $4.99 | $17.72 |
| 52 Week High | $5.99 | $44.28 |
Technical Indicators
Market Signals| Indicator | ACP | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 51.42 | 60.34 |
| Support Level | $5.13 | $22.88 |
| Resistance Level | $5.32 | $34.97 |
| Average True Range (ATR) | 0.05 | 1.81 |
| MACD | 0.01 | 0.07 |
| Stochastic Oscillator | 90.63 | 65.06 |
Price Performance
Historical ComparisonAbout ACP abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end management investment company. Its investment objective is to seek a high level of current income with a secondary objective of capital appreciation. It predominantly invests in debt and loan instruments of issues that operate in a variety of industries and geographic regions.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.